Drug class profile · refreshed daily from federal data

Cholinesterase Inhibitor

5 molecules in this class, $361.4M combined CY2024 Part D spend across 13.8M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Cholinesterase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $361.4Mcombined across class
Total Rx claims: 13.8M3.3M unique beneficiaries
Generic mfrs (active): 59across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Donepezil

Brand: Aricept · 12.3M Part D claims (CY24) · 2.9M beneficiaries · First FDA approval: 1996-11-25

20 generic mfrs 0 plans require PA

Low NADAC$0.044

→

Avg plan cost$0.132

Part D spend $158.0M 3× spread, current vs floor

Class share

44%

of class CY24 spend

View profile →

Rivastigmine

Brand: Exelon · 1.2M Part D claims (CY24) · 266K beneficiaries · First FDA approval: 2007-07-06

13 generic mfrs 0 plans require PA

Low NADAC$0.146

→

Avg plan cost$2.67

Part D spend $145.3M 18× spread, current vs floor

Class share

40%

of class CY24 spend

View profile →

Pyridostigmine

Brand: Mestinon · 424K Part D claims (CY24) · 125K beneficiaries · First FDA approval: 1955-04-06

11 generic mfrs 0 plans require PA

Low NADAC$0.249

→

Avg plan cost$1.62

Part D spend $57.5M 7× spread, current vs floor

Class share

16%

of class CY24 spend

View profile →

Malathion

Brand: Ovide · 3K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2014-01-31

1 generic mfrs 0 plans require PA

Low NADAC$3.19

→

Avg plan cost$3.19

Part D spend $515631 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Neostigmine Methylsulfate

Brand: Bloxiverz · — Part D claims (CY24) · First FDA approval: 2015-01-08

14 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.